Conditions (Title) | Interventions of clinical trial | Study type | Study completion |
---|---|---|---|
Metastatic breast cancer | • Drug: Placebo, veliparib, and carboplatin | Interventional, phase 2 | 2019 |
 • BRCA1 and BRCA2 mutation carrier with BC  • Hereditary BC/OC with BRCA1 and BRCA2 | • Drug: Letrozole, and placebo | Interventional, phase 3 | 2022 |
 • Recombinant hCG  • BRCA1 and BRCA2 mutation in BC | • Drug: Ovitrelle, and recombinant Hcg | Interventional phase 4 | 2021 |
 • OC, BC, and prostate cancer | • Drug: Olaparib | Interventional, phase 2 | 2018 |
 • BRCA1 and BRCA2 mutation carrier  • BC and metastatic BC, and OC | • Drug: Rucaparib (CO-338; AG-014699 or PF-01367338) • Expression evaluation | Interventional, phase 2 | 2015 |
 • BC metastatic  • BRCA1 and BRCA2 mutation carrier | • Drug: Olaparib therapy, and chemotherapy with doctor’s choice | Interventional, phase 3 | 2019 |
 • BRCA1 and BRCA2 mutation carrier in BC | • Biological: Therapeutic estradiol • Drug: Deslorelin, therapeutic testosterone • Deslorelin combined with low-dose add-back estradiol and testosterone | Interventional, phase 2 | 2019 |
 • BRCA1 and BRCA2 mutation carrier in BC | • Supplement: S0812: cholecalciferol supplementation | Interventional, not applicable | 2017 |
 • BC  • Metastatic BC  • BRCA1 and BRCA2 mutation | • Drug: ABT-888 and temozolomide | Interventional, phase 2 | 2020 |
 • Human EGF2 negative carcinoma of breast  • BRCA1 and BRCA2 mutation | • Drug: Niraparib as neoadjuvant therapy | Interventional, phase 1 | 2020 |
 • Breast neoplasms | • Drug: Dexamethasone, trabectedin | Interventional, phase 2 | 2011 |
 • Breast malignancy  • BRCA1 and BRCA2 mutation carrier | • Drug: Talazoparib (BMN 673) | Interventional, phase 2 | 2018 |
 • Breast neoplasms  • BRCA1 and BRCA2 mutation carrier | • Drug: Talazoparib (BMN 673): a PARP inhibitor • Drug: Physician’s choice | Interventional, phase 3 | 2019 |
 • Advanced BC  • HER2/Neu negative  • TNBC | • Drug: Talazoparib Tosylate | Interventional, phase 2 | 2019 |
 • BC: Stage IV  • OC  • BRCA1 and BRCA2 mutation | • Drug: Carboplatin, eribulin, and veliparib | Interventional, phase 2 | 2020 |
 • Basal-like breast carcinoma  • BRCA1 and BRCA2 mutation | • Drug: Veliparib • Laboratory evaluation and biomarker assessment | Interventional, phase 1 | 2017 |
 • Atypical ductal breast hyperplasia  • BRCA1 and BRCA2 mutation carrier | • Metformin hydrochloride as drug • Placebo | Interventional, phase 3 |  |
 • Atypical ductal breast hyperplasia  • BRCA1 and BRCA2 mutation | • Dietary supplement: curcumin • Biomarker evaluation | Interventional, not applicable | 2019 |